Are any lurbinectedin clinical trials studying pregnancy or fetal effects?
There is no information provided here indicating that lurbinectedin clinical trials are specifically designed to study its effects on fetuses.
What do we know about lurbinectedin and pregnancy risk?
From the information available, the key point is that lurbinectedin is being evaluated for cancer treatment, but no details are included about pregnancy-specific trial endpoints or fetal safety monitoring.
Where could trial listings mention fetal outcomes?
When fetal effects are being actively studied, trial records typically describe pregnancy-related eligibility, maternal-fetal monitoring, or outcomes specific to conception/pregnancy exposure. No such trial details are included in the provided information, so the presence or absence of fetus-focused studies can’t be confirmed.
Are there pregnancy-related trials for other reasons (not fetal endpoints)?
Even if a study is not designed around fetal effects, some cancer trials can still enroll patients who are (or become) pregnant, or they may collect exposure data for regulatory safety. However, the provided information does not say that lurbinectedin trials include these mechanisms.
If you share a trial identifier (e.g., NCT number) or a summary of where you saw the claim, I can help interpret whether that specific study includes pregnancy/fetal endpoints.